Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20471400 | 0.82 | ALDH1A1 (0.54) | KDM4EMAPTALDH1A1MEN1NPC1 | |
| SCHEMBL2632153 | 0.81 | MAPT (0.45) | KDM4EMAPK1MAPTALDH1A1POLB | |
| SCHEMBL11257563 | 0.78 | KMT2A (0.38) | POLBKMT2A | |
| SCHEMBL1847601 | 0.78 | DYRK1A (0.48) | KDM4EMAPTALDH1A1NPC1POLB | |
| SCHEMBL22728840 | 0.77 | MAPT (0.68) | MAPTMEN1NPC1LMNAPOLB | |
| SCHEMBL21630583 | 0.77 | MAPK1 (0.65) | MAPK1MAPTNPC1LMNAPOLB | |
| SCHEMBL24683497 | 0.76 | CFTR (0.41) | KDM4EMAPK1MAPTALDH1A1MEN1 | |
| SCHEMBL1925116 | 0.73 | GAA (0.67) | MAPK1MAPTALDH1A1NPC1LMNA | |
| SCHEMBL10321581 | 0.73 | KDM4E (0.46) | KDM4EMAPTALDH1A1SMN1; SMN2GAA | |
| SCHEMBL7730116 | 0.72 | MAPT (0.55) | MAPTMEN1NPC1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-04-09 | — | — | US | disclosed |
| US-12522594-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-01-13 | — | — | US | disclosed |
| EP-4626879-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Aligos Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4608821-A1 | PHARMACEUTICAL COMPOUNDS AS PARP7 AND/OR PARP1 INHIBITORS | Duke Street Bio Limited (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-3713931-B1 | 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | DEUTSCHES KREBSFORSCH (DE) | 2025-03-05 | — | — | EP | disclosed |
| CN-119212987-A | Methods and compositions for targeting PD-L1 | 安力高医药股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4448512-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Aligos Therapeutics, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240294505-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-09-05 | — | — | US | disclosed |
| US-20240277706-A1 | METHODS AND COMPOSTITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2019101643-A1 | 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-05-31 | — | — | WO | disclosed |
| WO-2018146010-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-16 | — | — | WO | disclosed |
| EP-2560967-B1 | Heterocyclic carboxylic acid amides as PDK1 inihibitors | BOEHRINGER INGELHEIM INT (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-8895581-B2 | 1H-imidazo[4,5-c]quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8575203-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2011144622-A1 | 1H - IMIDAZO [4, 5 - C] QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| WO-2010007114-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277706-A1 | METHODS AND COMPOSTITIONS FOR TARGETING PD-L1 | CD274, PDCD1, PDCD1LG2 | KDM4E 2919/4885MAPK1 145/4885MAPT 2186/4885 |
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, CBR1, CNR1 | KDM4E 1046/4885MAPK1 1783/4885MAPT 4854/4885 |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | PDK2, PDK4, CCNH | KDM4E 1191/4885MAPK1 436/4885MAPT 3636/4885 |
| US-20120094976-A1 | NEW CHEMICAL COMPOUNDS | CCNB1, MKI67, CCNA1 | KDM4E 911/4885MAPK1 426/4885MAPT 4068/4885 |
| US-20130210832-A1 | 1H-IMIDAZO[4,5-C]QUINOLINES | MKI67, CCNA1, CCNB1 | KDM4E 737/4885MAPK1 1275/4885MAPT 4491/4885 |
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | KDM4E 2935/4885MAPK1 56/4885MAPT 2382/4885 |
| US-20240294505-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, ARNT, HRH2 | KDM4E 818/4885MAPK1 3037/4885MAPT 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.